- $445.91m
- $387.58m
- $180.46m
Brief: Kamada Announces Planned Transition Of Chief Financial Officer
Brief: Kamada Q2 EPS USD 0.16
Brief: Kamada Announces FDA Approval Of Its New In-House Rabies Virus Neutralization Testing Laboratory
Brief: Kamada Q4 EPS USD 0.06
Brief: Kamada Reiterates 2025 FY Revenue Guidance Of $178M-$182M
NASDAQ RESUMED AT 07:20 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 06:55 AM
Brief: Kamada Q3 EPS USD 0.09
Brief: Kamada Enrolls First Patient In Trial Of CYTOGAM To Prevent CMV In Kidney Transplant Recipients
Brief: Kamada Reports Strong Second Quarter Financial Results
Brief: Kamada Sees FY revenue USD 156-160 million
Advisory: Alert wrongly tagged to Tel Aviv Stock Exchange Ltd withdrawn
Brief: Kedrion Announces Eight-Year Extension Of Distribution Agreement With Kamada In US For Kedrab
Brief: Kamada Announces Its Largest Commercial Agreement A Strategic Engagement With Kedrion For U.S. Distribution Of Kedrab® Including $180 Million Of Revenues Over First Four Years
Brief: Kamada Q3 EPS USD 0.07
Following FDA Approval Of Technology Transfer Process, Cytogam Manufactured By Co At Facility Now Available For Commercial Sales In U.S.
Brief: Kamada Announces Recent Achievements With CYTOGAM® Including Availability Of Product Manufactured By The Company For U.S Commercial Sale And Presentation Of New Clinical Data
Brief: Kamada Continues To Conduct Business Operations In Israel With No Effect On Business Continuity
Brief: Kamada Ltd Files For Shelf Of Up To $50 Million Ordinary Shares – SEC Filing